Quidel deal

Lilly announced last January that it would sell Pacific Biotech as part of a plan to separate its medical devices and diagnostics business from its core pharmaceutical business.

QDEL said it holds 14 percent of the $40 million U.S. professional pregnancy test market, while Pacific Biotech holds 13 percent. QDEL said it holds 4 percent of the $50 million U.S. strep test market, while Pacific Biotech accounts for 11 percent. Both companies sell through medical distributors. ...